Biotech Values

[mcbio]

What drug do you think CLDX is planning to launch? Certainly not 011. And Rindo is rather a long ways off.

CLDX did say in the call that for CDX-1135 against dense deposit disease (DDD) they think there could be a modestly sized registration strategy for the drug and that they have the FDA's agreement with their strategy for the drug. The Phase 2 pilot study will initiate later this year. CLDX claims the drug showed clear biological activity for strong renal function and reversing kidney damage in animals with DDD and blocking complement activity in earlier human clinical trials. So, perhaps they're hoping to take 1135 to market themselves.